CDMOs-Injectables: Tariff Impact: Are Capacity Shifts in the Making?
Sponsored by Vetter Pharma International GmbH
What will be the impact of US tariffs on CDMOs of injectables and on the decision-making of pharma companies on in-sourced/outsourced activity overall and in key geographic markets: Europe, Canada, India and China? How will major segments, innovator drug and generics/biosimilars, be affected?
Featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting, where he focuses on healthcare and life sciences, including pharmaceuticals and vaccines, and leads L.E.K.’s Pharmaceutical Contract Services Practice.
Each episode of the Production to Prescription podcast is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights. Or get each episode through:
DCAT Value Chain Insights’ Production to Prescription podcast features thought leaders with expert views on the major happenings impacting the global bio/pharmaceutical manufacturing value chain and industry performance. ICYMI, other recent episodes include:
“Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025?,” featuring Arda Ural, EY America Life Sciences Leader, Ernst & Young (EY)
“Global API Outlook: Will Supply Lines Change Amid Tariff Uncertainty?,” featuring Julia Morilla, Associate Content Analyst, Cortellis Product Intelligence, Clarivate
“Biomanufacturing: How are Industry Capacity & Supply Chains Trending?,” featuring Eric Langer, MBA, Managing Partner & President, BioPlan Associates, and Renaud Jacquemart, PhD, MBA, Senior Advisor, BioPlan Associates;
“Parenteral Drug Manufacturing—CDMO Outlook: A Capacity Crunch or Easing?,” featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting and Head of L.E.K.’s Pharmaceutical Contract Services Practice; and
“Bio/Pharma Industry Outlook, Supply Chains 2025: The Year Ahead,” featuring Derron Stark, EY-Parthenon Partner, Strategy & Transactions – Health Sciences & Wellness, Supply Chain, Ernst & Young LLP.
